Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Short Interest Update

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 758,697 shares, a growth of ? from the April 30th total of 0 shares. Based on an average trading volume of 622,622 shares, the short-interest ratio is presently 1.2 days. Currently, 1.7% of the shares of the company are sold short.

Insider Transactions at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the purchase, the director directly owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. The trade was a 77.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders bought 2,902,872 shares of company stock worth $53,769,784 in the last 90 days.

Analyst Ratings Changes

Several research analysts have recently commented on COAG shares. Jefferies Financial Group started coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price on the stock. Evercore assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price for the company. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.75.

Hemab Therapeutics Stock Performance

Shares of NASDAQ COAG traded up $0.34 during mid-day trading on Tuesday, hitting $27.47. The company had a trading volume of 194,537 shares, compared to its average volume of 221,907. Hemab Therapeutics has a one year low of $23.00 and a one year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.